Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VCA followed by D-MAG for elderly untreated AML
ChiCTR2200061925Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Jul 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax, tucidinostat, azacitidine, decitabine and magnesium in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Event-free survival. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
venetoclaxtucidinostatazacitidinedecitabinemagnesium
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2200061925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061925.